Bio Rad

Redmond, WA, United States
Redmond, WA, United States

Time filter

Source Type

HERCULES, CA--(Marketwired - May 24, 2017) - Bio-Rad Laboratories, Inc. ( : BIO) ( : BIOb), a global provider of life science research and clinical diagnostic products, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for enhanced capability with its IH-Com data management software to manage patient results with the company's IH-1000 automated blood typing instrument. The IH-1000 blood typing instrument and a wide variety of associated gel cards have been commercially available in the U.S. since October 2016. IH-Com is a powerful data management tool that combines all current and prior results associated with a patient and delivers an overall interpretation and crosscheck. IH-Com can link instruments together at a lab and at other locations as well, and it facilitates the transfer of data to a laboratory information system (LIS). With the most recent clearance, users have additional options to automate the release of test results to the laboratory's LIS system, while continuing to ensure safe and accurate patient results. "We are pleased that the FDA has cleared our IH-Com data management software with expanded options for our customers in the U.S," said John Hertia, Bio-Rad Executive Vice President and President, Clinical Diagnostics Group. "The expanded options can lead to a more rapid and efficient delivery of safe and accurate patient results, significant workflow improvements, and overall a more lean laboratory operation." About Bio-Rad Bio-Rad Laboratories, Inc. ( : BIO) ( : BIOb) develops, manufactures, and markets a broad range of innovative products and solutions for the life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and healthcare industry customers through its global network of operations. The Company employs more than 8,250 people worldwide and had revenues exceeding $2 billion in 2016. For more information, please visit www.bio-rad.com. Bio-Rad Forward-Looking Statements This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding plans to introduce new products and the opportunities that may result from such new products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "plan", "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in Bio-Rad's public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.


News Article | May 4, 2017
Site: www.marketwired.com

HERCULES, CA--(Marketwired - May 4, 2017) - Bio-Rad Laboratories, Inc. ( : BIO) ( : BIO.B), a global provider of life science research and clinical diagnostic products, announced financial results today for the first quarter ended March 31, 2017. First-quarter 2017 reported revenues were $500.1 million, an increase of 6.1 percent compared to $471.2 million reported for the first quarter of 2016. On a currency-neutral basis, quarterly revenues increased 6.7 percent compared to the same period last year. First-quarter 2017 gross margin was 54.0 percent compared to 56.0 percent during the same quarter last year. The decrease in gross margin during the first quarter of 2017 was primarily the result of a $10 million one-time expense associated with the acquisition of RainDance Technologies, Inc., which was completed in February 2017. The Life Science segment net sales in the first quarter of 2017 were $174.3 million, an increase of 5.1 percent compared to the same period last year. On a currency-neutral basis, Life Science segment sales increased 6.3 percent compared to the first quarter in 2016. Performance for the first quarter benefitted from sales of our Droplet Digital™ PCR instruments and reagents, western blotting imagers, and PCR food testing products, partially offset by a decline in process media product sales. The currency neutral sales increase was reflected in Europe, China, and Asia Pacific, partially offset by slowness in Latin America and Japan. Net sales for the Clinical Diagnostics segment in the first quarter of 2017 were $322.3 million, an increase of 6.8 percent compared to the first quarter of 2016. On a currency-neutral basis, Clinical Diagnostics sales increased 7.0 percent compared to the same period last year. Results from the first quarter reflected growth across immunology, quality control, and blood typing products. Sales growth also benefitted from some early product shipments in advance of the European implementation of our ERP system. Strong growth in Europe, Latin America, and China was partially offset by slower sales in North America and Japan. Net income for the first quarter of 2017 was $12.4 million, or $0.41 per share on a fully diluted basis, compared to $12.3 million, or $0.42 per share during the same period last year. Net income for the first quarter of 2017 versus the first quarter of 2016 was essentially flat and primarily the result of lower margins, increased SG&A expenses, and costs associated with the establishment of a new European operating model, partially offset by an increase in contingent consideration benefit. The following table compares certain non-cash or non-recurring items from Q1 2017 to Q1 2016: The effective tax rate for the first quarter of 2017 was 38 percent, compared to a tax rate of 39 percent for the same quarter in 2016. The tax rate in 2016 and 2017 was higher than the U.S. federal statutory tax rate due to foreign losses for which no benefit is expected. "We are encouraged by our overall performance in the first quarter, with many of our key products lines and regions posting solid growth," said Norman Schwartz, Bio-Rad President and Chief Executive Officer. "Although our continued investments in our operations tempers our profitability in the short term, these investments will help us drive growth and improved profitability throughout the company in the years to come." In February, Bio-Rad acquired RainDance Technologies, Inc., a Massachusetts-based company with droplet-based solutions that offer ultra-sensitive detection of genetic variations in cancer, as well as inherited and infectious diseases, enabling research in areas such as non-invasive liquid biopsy. Also during the first quarter, Bio-Rad and Illumina, Inc. announced the launch of the Illumina® Bio-Rad® Single-Cell Sequencing Solution, the first next-generation sequencing (NGS) workflow that enables a deep view into the gene expression of individual cells to better understand their functions in complex tissues. For the full year 2017, the Company continues to anticipate currency neutral revenue growth of approximately 4 percent and improved profitability with a currency neutral operating margin target of 7 percent. This current estimate does not include the impacts of the recent acquisition of RainDance. Management will discuss this outlook in greater detail on the first-quarter 2017 financial results conference call. "While 2017 will be another year of relatively modest operating margin, we remain committed to successfully completing these foundational investments, which will allow us to realize significant improvement in profitability in the medium term and drive sustainable shareholder value over the long term," Mr. Schwartz said. Management will discuss these results in a conference call at 2 PM Pacific Daylight Time (5 PM Eastern Daylight Time) May 4, 2017. Interested parties may access the call at 855-779-9068 within the U.S. or 631-485-4862 outside the U.S., conference ID: 3156057. You may also listen to the conference call live via a webcast that is available on the "Investor Relations" section of our website under "Quarterly Results" at www.bio-rad.com. The webcast will be available for up to a year. About Bio-Rad Bio-Rad Laboratories, Inc. ( : BIO) ( : BIO.B) develops, manufactures, and markets a broad range of innovative products and solutions for the life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and healthcare industry customers through its global network of operations. The Company employs more than 8,250 people worldwide and had revenues exceeding $2 billion in 2016. For more information, please visit www.bio-rad.com. This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding estimated future financial performance or results, the growth of our business, expectations regarding operating margin and foundational investments, realizing significant improvement in profitability in the medium term, driving sustainable shareholder value over the long term, our expectations regarding our products and our release of new products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include our ability to develop and market new or improved products, difficulties in implementing our global enterprise resource planning system, our ability to compete effectively, our ability to integrate acquired companies, products or technologies into our company successfully, foreign currency exchange fluctuations, product quality and liability issues, recent and planned changes to our global organizational structure and executive management team, international legal and regulatory risks, reductions in government funding or capital spending of our customers, supply chain issues, changes in the healthcare industry, global economic conditions, and natural disasters and other catastrophic events beyond our control. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's public reports filed with the Securities and Exchange Commission (the "SEC"), including the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2016, and its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2017 to be filed with the SEC. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc. disclaims any obligation to update these forward-looking statements.


HERCULES, CA--(Marketwired - Jun 12, 2017) - Bio-Rad Laboratories, Inc. ( : BIO) and ( : BIO.B), a global provider of life science research and clinical diagnostic products, today announced it has received U.S. Food and Drug Administration (FDA) clearance for its BioPlex® 2200 Syphilis Total & RPR assay, a novel one-step universal testing method to aid in the diagnosis of syphilis infection. The BioPlex 2200 Syphilis Total & RPR (rapid plasma reagin) assay offers laboratories the first fully automated Treponemal/non-Treponemal dual assay, which simultaneously detects antibodies to T. pallidum and reagin antibodies as well as RPR titer (the level of antibody) determination for effective treatment monitoring. Compared to traditional manual RPR card tests, the automation of RPR testing offers labor savings, objective result reporting, and improved workflow to laboratories. "The addition of the BioPlex 2200 Syphilis Total & RPR assay broadens our expanding BioPlex 2200 System infectious disease menu while offering laboratories a simplified approach to syphilis testing, and it is adaptable to any testing algorithm used by a laboratory," said John Hertia, Bio-Rad President, Clinical Diagnostics Group. The release of the BioPlex 2200 Syphilis Total & RPR assay is the latest offering in Bio-Rad's growing infectious disease menu for the BioPlex® 2200 System, a fully automated multiplex technology platform. The BioPlex 2200 System provides clinical laboratories the capability to rapidly process or "multiplex" multiple individual tests that are traditionally processed separately, conserving patient sample volume and simplifying workflow. About Bio-Rad Bio-Rad Laboratories, Inc. ( : BIO) and ( : BIO.B) develops, manufactures, and markets a broad range of innovative products and solutions for the life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and healthcare industry customers through its global network of operations. The Company employs more than 8,350 people worldwide and had revenues exceeding $2 billion in 2016. For more information, please visit www.bio-rad.com. Bio-Rad Forward-Looking Statements This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding plans to introduce new products and the opportunities that may result from such new products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "plan", "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "offers," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in Bio-Rad's public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.


News Article | August 3, 2017
Site: www.marketwired.com

HERCULES, CA--(Marketwired - Aug 3, 2017) - Bio-Rad Laboratories, Inc. ( : BIO) and ( : BIO.B), a global provider of life science research and clinical diagnostic products, announced financial results today for the second quarter ended June 30, 2017. Second-quarter 2017 net sales were $504.7 million, a decrease of 2.3 percent compared to $516.8 million reported for the second quarter of 2016. On a currency-neutral basis, quarterly net sales decreased 1.6 percent compared to the same period last year. The sales decline in the second quarter of 2017 was largely due to a slowdown in productivity related to the recent go-live of our global ERP system in Western Europe as well as the absence of sales that were pulled forward into the first quarter in anticipation of our ERP deployment. The Life Science segment net sales in the second quarter of 2017 were $179.4 million, a decrease of 0.3 percent compared to the same period last year. On a currency-neutral basis, Life Science segment sales increased 0.3 percent compared to the second quarter of 2016. Currency neutral sales growth was primarily driven by sales of Droplet Digital PCR (ddPCR) instruments and reagents, offset by a decline in process chromatography media sales, as well as some of the ERP-related disruption mentioned above. Also, during the quarter the Life Science segment posted increases from the acquisition of RainDance Technologies. The currency neutral sales increase was reflected in North America, China, and Asia Pacific, offset by slowness in Europe, Latin America and Japan. Net sales for the Clinical Diagnostics segment in the second quarter of 2017 were $322.1 million, a decrease of 3.5 percent compared to the second quarter of 2016. On a currency-neutral basis, sales decreased 2.7 percent compared to the same period last year. Results from the second quarter reflected a substantial slowdown of European sales, especially in infectious disease and immunohematology products, directly related to the disruptions post go-live of the new ERP system. The currency neutral sales results also reflected slowness in the Americas, partially offset by growth in Asia. Net income for the second quarter of 2017 was $5.0 million, or $0.17 per share on a fully diluted basis, compared to $18.0 million, or $0.61 per share during the same period last year. Net income for the second quarter of 2017 versus the second quarter of 2016 was negatively impacted by the lower sales and corresponding lower gross profit as well as increased acquisition-related expenditures for new products and technology and higher expense for the implementation of new systems and operations in Europe. "The second quarter of 2017 has been one of our most challenging with sales growth being significantly tempered by the slowing of productivity resulting from our major ERP deployment in Western Europe as well as from lower than expected sales in our process media business and in the Americas," said Norman Schwartz, Bio-Rad President and Chief Executive Officer. "These sales results, along with substantial spending related to implementing new systems and operations in Europe, as well as increased expenditures for newly acquired products and technology, combined to produce a disappointing operating result for the quarter. However, we remain confident that these investments will lead to increased sales and margin expansion over the coming years," added Mr. Schwartz. The following table compares certain non-cash or non-recurring items from Q2 2017 to Q2 2016: The effective tax rate for the second quarter of 2017 was a 350 percent benefit, compared to a tax rate of 33 percent for the same quarter in 2016. The unusually low tax rate used in the second quarter of 2017 reflects discrete tax benefits related to share-based compensation as well as the transfer of intangibles related to our European reorganization. On a reported basis, net sales for the first half of 2017 increased 1.7 percent to $1.0 billion compared to $988.0 million for the same period in 2016. On a currency-neutral basis, net sales grew 2.3 percent. Year-to-date net income for 2017 was $17.4 million, or $0.58 per share on a fully diluted basis, compared to $30.3 million, or $1.03 per share, respectively, during the same period in 2016. 2017 Financial Outlook For the full year 2017, the Company continues to anticipate currency-neutral organic sales growth of approximately 4 percent, which assumes a substantial portion of the lower revenue due to the transition to a new ERP system will be recovered by the end of the year. Further, the addition of the recently acquired RainDance Technologies could add up to another 1 percent of growth in sales for the full year. With the lower than anticipated operating profit in the first half of 2017 and including the addition of RainDance, the Company is lowering its estimate for currency-neutral operating profit for the full year from the previously stated 7 percent of sales to now be in the 6 to 6.5 percent range. "While 2017 will be another year of relatively modest operating margin especially with the inclusion of substantial acquisition-related expense, we are focused on completing these foundational investments and harvesting the benefits of a more efficient and cost effective operating model," Mr. Schwartz said. "We look forward to sharing more insight to our long term plans with the investment community at our Investor Day to be held in New York later this year." Management will discuss these results in a conference call at 2 PM Pacific Daylight Time (5 PM Eastern Daylight Time) August 3, 2017. Interested parties may access the call at 855-779-9068 within the U.S. or 631-485-4862 outside the U.S., conference ID: 50367493. You may also listen to the conference call live via a webcast that is available on the "Investor Relations" section of our website under "Quarterly Results" at www.bio-rad.com. The webcast will be available for up to a year. About Bio-Rad Bio-Rad Laboratories, Inc. ( : BIO) and ( : BIO.B) develops, manufactures, and markets a broad range of innovative products and solutions for the life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and healthcare industry customers through its global network of operations. The Company employs more than 8,350 people worldwide and had net sales exceeding $2 billion in 2016. For more information, please visit www.bio-rad.com. This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding estimated future financial performance or results, the growth of our business, our ability to recover revenue, expectations regarding operating margin and foundational investments, realizing increased sales and margin expansion over the coming years, our expectations regarding the recently acquired RainDance Technologies and regarding our products and our release of new products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "assume", "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include our ability to develop and market new or improved products, difficulties in implementing our global enterprise resource planning system, our ability to integrate acquired companies, products or technologies into our company successfully, our ability to compete effectively, foreign currency exchange fluctuations, recent and planned changes to our global organizational structure and executive management team, product quality and liability issues, international legal and regulatory risks, reductions in government funding or capital spending of our customers, supply chain issues, changes in the healthcare industry, global economic conditions, and natural disasters and other catastrophic events beyond our control. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's public reports filed with the Securities and Exchange Commission (the "SEC"), including the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2016, and its Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2017 to be filed with the SEC. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc. disclaims any obligation to update these forward-looking statements.


News Article | October 28, 2016
Site: www.marketwired.com

HERCULES, CA--(Marketwired - Oct 24, 2016) - Bio-Rad Laboratories, Inc. ( : BIO) and ( : BIO.B), a global provider of life science research and clinical diagnostic products, today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for its IH-1000 blood typing instrument along with approvals for a wide range of associated gel cards and reagents for the U.S. blood typing market. The system offers full automation and walk-away reliability, allowing laboratories to more efficiently manage their blood testing workload. With the release of the IH-1000 system and associated gel cards and reagents, Bio-Rad offers a wide variety of platforms, reagents, data management, and connectivity solutions to support different volume blood testing needs of the U.S. market. These products include Bio-Rad's TANGO infinity™ system as well as a comprehensive range of reagents for conventional tube testing. "We are pleased the FDA has cleared the way for us to bring the IH-1000 and associated products to the U.S.," said John Hertia, Bio-Rad Executive Vice President and President, Clinical Diagnostics Group. "With the availability of the IH-1000 system and gel cards, our TANGO infinity™ system, along with our comprehensive line of reagents, data management, and networking capability, customers now have the convenience and flexibility to select product solutions to optimize their laboratory workflow," he added. The IH-1000 system includes the IH-1000 automated instrument, a wide range of gel cards, associated reagents, and IH-Com software for managing data and patient results and connections to the laboratory information system (LIS). The IH-1000 instrument is designed for rapid sample processing with continuous access, and it incorporates a number of important safety features. Together, these solutions offer our customers efficient and reliable results for blood grouping, reverse grouping, phenotyping, cross matching, antibody screening, antibody identification, direct AHG tests, and single antigen screens. About Bio-Rad Bio-Rad Laboratories, Inc. ( : BIO) and ( : BIO.B) develops, manufactures, and markets a broad range of innovative products and solutions for the life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and healthcare industry customers through its global network of operations. The company employs more than 8,000 people worldwide and had revenues exceeding $2 billion in 2015. For more information, please visit www.bio-rad.com.


News Article | November 1, 2016
Site: www.marketwired.com

HERCULES, CA--(Marketwired - Nov 1, 2016) - Bio-Rad Laboratories, Inc. ( : BIO) and ( : BIO.B), a global provider of life science research and clinical diagnostic products, announced financial results today for the third quarter ended September 30, 2016. Third-quarter reported revenues were $508.7 million, an increase of 8.3 percent compared to $470.0 million reported for the third quarter of 2015. On a currency-neutral basis, quarterly revenues increased 9.1 percent compared to the same period last year. Third-quarter gross margin was 54.9 percent compared to 56.1 percent during the same quarter in 2015. The year-over-year decrease in gross margin during the third quarter of 2016 compared to the same period last year was primarily due to product mix and increased instrument placements, as well as higher manufacturing and service costs. Net income for the third quarter was $18.4 million, or $0.62 per share on a fully diluted basis, compared to $17.4 million, or $0.59 per share during the same period last year. Net income for the third quarter of 2016 reflects several items that increased SG&A expenses including costs associated with the continued implementation of our global ERP system and various legal matters. Research & development (R&D) expenses also increased during the third of quarter 2016 compared to the same period last year. The effective tax rate for the third quarter of 2016 was 19 percent, compared to the tax rate of 32 percent during the same period last year. The lower tax rate in 2016 was primarily due to adjustments related to U.S. federal taxes. Year-to-date revenues were $1.50 billion, an increase of 3.3 percent compared to $1.45 billion reported in the first three quarters of 2015. Adjusting for the impact of currency, year-to-date revenue growth for the first nine months of 2016 was 5.2 percent. Year-to-date net income for the first three quarters of 2016 was $48.7 million, or $1.65 per share on a fully diluted basis, compared to $63.6 million, or $2.17 per share reported during the same period in 2015. The year-over-year decrease in net income was primarily the result of lower margins, an increase in SG&A expenses including $9.5 million in restructuring costs coordinated with the implementation of our global ERP system, $10.1 million in costs associated with various legal matters, and an increase in R&D expense. "We are pleased with a strong sales performance in the third quarter, in particular, our life science business, with nearly 20 percent currency-neutral growth," said Norman Schwartz, Bio-Rad President and Chief Executive Officer. "Continued investments in our operations have affected profitability for the first nine months of the year, but these investments are necessary to support our growth." Life Science The Life Science segment net sales for the third quarter were $178.1 million, an increase of 18.4 percent compared to the same period last year. On a currency-neutral basis, the Life Science segment sales were up 19.3 percent compared to the third quarter of 2015. Results from the third quarter benefitted from increased sales of Droplet Digital™ PCR and process media products. Sales for the Life Science segment reflected growth across all regions. During the quarter Bio-Rad announced the launch of two residual DNA quantification (RDQ) kits designed for use with the Company's Droplet Digital™ PCR Systems. The kits simplify the quantification of host-cell DNA (HCD) in process development, quality control, and biomanufacturing processes. Clinical Diagnostics Reported net sales for the Clinical Diagnostics segment in the third quarter were $327.1 million, an increase of 3.5 percent compared to the third quarter in 2015. On a currency-neutral basis, the Clinical Diagnostics segment sales increased 4.4 percent. Results from the second quarter reflected significant growth across several product lines, most notably clinical immunology, diabetes, and quality controls. Sales growth in North America and Asia Pacific was partially offset by markets in Western Europe and Japan. In August, the Company introduced Amplichek™ I quality control, one in a series of infectious disease controls that Bio-Rad has introduced for the molecular diagnostic testing market this year. Management will discuss these results in a conference call at 2 PM Pacific Time (5 PM Eastern Time) November 1, 2016. Interested parties may access the call at 855-779-9068 within the U.S. or 631-485-4862 outside the U.S., conference ID: 93613814. You may also listen to the conference call live via a webcast that is available on the "Investor Relations" section of our website under "Quarterly Results" at www.bio-rad.com. The webcast will be available for up to a year. About Bio-Rad Bio-Rad Laboratories, Inc. ( : BIO) and ( : BIO.B) develops, manufactures, and markets a broad range of innovative products and solutions for the life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and healthcare industry customers through its global network of operations. The company employs more than 8,000 people worldwide and had revenues exceeding $2 billion in 2015. For more information, please visit www.bio-rad.com. This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding the growth of our business, our release of new products and future financial performance. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "plan," "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include our ability to develop and market new or improved products, our ability to compete effectively, difficulties in implementing our global enterprise resource planning system, recent and planned changes to our global organizational structure and executive management team, foreign currency exchange fluctuations, international legal and regulatory risks, reductions in government funding or capital spending of our customers, our ability to integrate acquired companies, products or technologies into our company successfully, product quality and liability issues, supply chain issues, changes in the healthcare industry, global economic conditions, and natural disasters and other catastrophic events beyond our control. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's public reports filed with the Securities and Exchange Commission (the "SEC"), including the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2015, and its Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2016 to be filed with the SEC. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc. disclaims any obligation to update these forward-looking statements.


News Article | February 23, 2017
Site: www.marketwired.com

HERCULES, CA--(Marketwired - Feb 23, 2017) - Bio-Rad Laboratories, Inc. ( : BIO) ( : BIO.B), a global provider of life science research and clinical diagnostic products, today announced financial results for the fourth quarter and fiscal year ended December 31, 2016. Fourth-quarter 2016 reported revenues were $571.5 million, an increase of 0.2 percent compared to $570.6 million reported for the fourth quarter of 2015. On a currency-neutral basis, quarterly revenues increased 0.8 percent compared to the same period in 2015. Fourth-quarter gross margin was 55.0 percent compared to 54.1 percent during the fourth quarter in 2015. Life Science segment net sales for the fourth quarter were $206.8 million, a decrease of 5.2 percent compared to the same period in 2015. On a currency-neutral basis, Life Science segment sales decreased by 4.3 percent. As noted during our third-quarter 2016 earnings conference call, revenues were unusually low for the third quarter of 2015 due to the rollout of our ERP system in our Life Science segment. As a result, performance in the fourth quarter of 2015 was unusually strong; this atypical situation results in a difficult year-over-year comparison for the same period in 2016. Underlying this comparison was good growth of Droplet Digital™ PCR and food testing products. Clinical Diagnostics segment net sales for the fourth quarter were $360.8 million, an increase of 3.5 percent compared to the same period in 2015. On a currency-neutral basis, net sales were up 4.0 percent. Results from the fourth quarter were primarily attributed to growth in diabetes, immunology, and quality control product lines. The fourth quarter of 2016 showed a net loss of $20.6 million, or $0.70 per share on a diluted basis, compared to net income of $49.5 million, or $1.68 per share during the same period in 2015. The decrease in net income was largely due to several non-cash charges including $59.9 million goodwill and in-process research & development (IPR&D) impairment, increases in expenses related to the revaluation of contingent consideration, and increases in certain legal reserves. The following table compares these items from Q4 2016 to Q4 2015: The effective tax rate for the fourth quarter of 2016 was 27.0 percent compared to 8.7 percent for the same period in 2015. The lower effective tax rate in 2015 was due to the tax benefit of foreign repatriations and the permanent reinstatement of the federal R&D credit in the fourth quarter of 2015. For the full year of 2016, net sales were $2,068.2 million compared to $2,019.4 million in 2015, an increase of 2.4 percent. On a currency neutral basis, sales increased by 4.0 percent. Full-year gross margin was 55.0 percent compared to 55.5 percent reported in 2015. Full-year reported sales for the Life Science segment were $730.7 million, an increase of 5.1 percent compared to the same period in 2015. On a currency-neutral basis, full-year sales increased 6.5 percent. Full-year reported revenues for the Clinical Diagnostics segment were $1,323.3 million, an increase of 1.0 percent compared to the same period in 2015, or an increase of 2.6 percent on a currency-neutral basis. Full-year net income in 2016 was $28.1 million, or $0.95 per share on a fully diluted basis, compared to $113.1 million, or $3.85 per share in 2015. The year-over-year decrease in net income was primarily the result of lower margins, $62.3 million in non-cash impairment of goodwill and long-lived assets, increased SG&A expenses associated with various legal matters, $11.7 million in restructuring costs associated with the upcoming implementation of our global ERP system in Western Europe, and increased purchase accounting. The following table compares certain non-cash or non-recurring items from 2016 to 2015: The effective tax rate in 2016 was 32.3 percent compared to 22.5 percent in 2015. The effective tax rate for 2016 and 2015 included a tax benefit of $16.8 million and $6.3 million, respectively, for foreign repatriations. The effective tax rate for 2016 included additional tax liabilities for unrecognized tax benefits of $17.5 million related to the non-deductibility of interest expense in foreign jurisdictions. "We are encouraged by our overall topline performance for the year, which was higher than our guidance," said Norman Schwartz, Bio-Rad President and Chief Executive Officer. "All of this growth is organic and represents good progress for the year. Although our continued investment in our operations coupled with unusual expenses during the year affected our profitability, these investments are necessary to support growth and improved profitability for the years to come." In January, 2017 Bio-Rad announced that it had entered into a definitive agreement to purchase RainDance Technologies, Inc. Bio-Rad completed the transaction in February, acquiring RainDance for an estimated $87 million plus certain assumed net liabilities. RainDance's intellectual property portfolio and product lines encompass a wide range of biological reactions in droplets, with applications in life science research and clinical research. These genomic tools provide ultra-sensitive detection of genetic variations in cancer as well as inherited and infectious diseases, enabling research in areas such as non-invasive liquid biopsy. "We welcome the opportunity to expand our product offering with RainDance products and technologies," Mr. Schwartz said. "Our combined droplet-based solutions will enable life science and clinical diagnostics customers to implement a broad range of applications that include digital PCR and next-generation sequencing." 2017 Financial Outlook For the full year 2017, the Company anticipates continued strength with currency neutral revenue growth of approximately 4 percent, and improved profitability with a currency neutral operating margin of 7 percent. This current estimate does not include the impacts of the recent acquisition of RainDance. Management will discuss this outlook in greater detail on the fourth-quarter and full-year 2016 financial results conference call. "While 2017 will be another year of relatively modest operating margin, we are committed to successfully completing these foundational investments, which will allow us to realize significant improvement in profitability in the medium term and drive sustainable shareholder value over the long term," Mr. Schwartz said. Management will discuss these results in a conference call at 2 PM Pacific Time (5 PM Eastern Time) February 23, 2017. Interested parties may access the call at 855-779-9068 within the U.S. or 631-485-4862 outside the U.S., conference ID: 56053006. You may also listen to the conference call via a webcast that is available in the "Investor Relations" section of our website under "Quarterly Results" at www.bio-rad.com. The webcast will be available for up to a year. About Bio-Rad Bio-Rad Laboratories, Inc. ( : BIO) ( : BIO.B) develops, manufactures, and markets a broad range of innovative products and solutions for the life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and healthcare industry customers through its global network of operations. The Company employs more than 8,250 people worldwide and had revenues exceeding $2 billion in 2016. For more information, please visit www.bio-rad.com. This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding estimated future financial performance or results, the growth of our business, expectations regarding operational investments, realizing significant improvement in profitability in the medium term, driving sustainable shareholder value over the long term, our release of new products and our expectations regarding our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include our ability to develop and market new or improved products, difficulties in implementing our global enterprise resource planning system, our ability to compete effectively, foreign currency exchange fluctuations, product quality and liability issues, recent and planned changes to our global organizational structure and executive management team, our ability to integrate acquired companies, products or technologies into our company successfully, international legal and regulatory risks, reductions in government funding or capital spending of our customers, supply chain issues, changes in the healthcare industry, global economic conditions, and natural disasters and other catastrophic events beyond our control. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's public reports filed with the Securities and Exchange Commission (the "SEC"), including the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2015, and its Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2016, and its Annual Report on Form 10-K for the fiscal year ended December 31, 2016 to be filed with the SEC. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc. disclaims any obligation to update these forward-looking statements.


News Article | November 3, 2016
Site: www.prnewswire.co.uk

Gene Editing Market size will reach USD 7.5 billion by 2024; as per a new research report by Global Market Insights, Inc. Increasing prevalence of cancer and other genetic disorders coupled with growing preference for personalized medicine will stimulate global genome editing market size. Furthermore, improved healthcare infrastructure, introduction of novel treatment alternatives and rising R&D spending by pharma and biotech companies should propel industry growth. Request for a sample of this research report @ https://www.gminsights.com/request-sample/detail/810 Global gene editing market size may be hindered by stringent government regulations for approval to gene mutation projects and lack of awareness among people regarding the safety of genetic interventions. Hematology led the genome editing market share with over USD 807 million in 2015. Infectious diseases will grow at 15.1% CAGR during the forecast period due to growing use of gene editing techniques for detection of infectious diseases such as HIV. Biotech and pharma sectors dominated the industry with over USD 1,278 million revenue for 2015, owing to several applications in drug discovery and therapeutics. With the increasing use of CRISPR and ZFN, companies are capitalizing on innovative researches focusing on development of engineering techniques. CROs will see strong growth due to the significant trend of outsourcing complex drug discovery processes by pharmaceutical companies. U.S. gene editing market share led the global industry with USD 518.5 million in 2015 owing to advancement in biotechnology and pharmaceutical industry and rising prevalence of Alzheimer, dementia, cancer and infectious diseases. China gene editing market size will witness robust growth over forecast period due to rising R&D expenditure and growing number of gene editing companies.  China will show significant growth during the forecast period due to various initiatives taken by the Chinese government for promoting life science research in biotechnology sector. Browse key industry insights spread across 150 pages with 90 market data tables & 7 figures & charts from the report, "Gene Editing Market Size By Technology (CRISPR/Cas9, Zinc Finger Nucleases (ZFNs), Meganucleases, TALENS), By Application (Hematology, Infectious Disease, Oncology, Muscular Disorders), By End User (Biotech and Pharma, CRO, Research Institutes) Industry Analysis Report, Regional Outlook (U.S., Canada, UK, Spain, Russia, Poland, China, Japan, India, Australia, Malaysia, Mexico, Brazil, Argentina, South Africa, Saudi Arabia, Israel), Application Potential, Price Trends, Competitive Market Share & Forecast, 2016 - 2024" in detail along with the table of contents: Global gene editing market size will reach USD 7.5 billion by 2024 growing at 14.9% CAGR from 2016 to 2024, owing to rising demand for synthetic genes and increased production of genetically modified crops and organisms. CRISPR technology is the fastest growing segment with business revenue expected to exceed USD 3 billion by 2024 owing to wider applications in genetic engineering and the speed and specificity of edits carried out using it. The technology received the U.S. approval for human trial to treat certain cancers such as myeloma, melanoma and sarcoma. Oncology will witness robust 15.9% CAGR over forecast period. Cancer will remain one of the leading causes of death globally. The business segment should exceed USD 874 million by 2024 owing to growing prevalence of various types of cancers. UK genome editing market share accounted for over 41% of regional revenue size growing at 14.9% to reach USD 744 million by 2024. Increasing geriatric population along with growing prevalence of chronic diseases will fuel business growth. Key industry players include Agilent Technologies, Allele Biotech, Bio Rad, AstraZeneca, CRISPR Therapeutics, Dharmacon, Cellectis, Editas Medicine, GE Healthcare Lonza, Qiagen, Recombinetics, SIGMA-Aldrich and Thermo Fisher Scientific. Companies are consolidating their industry position by increasing their focus on research activities to develop new cost effective technologies. Make an inquiry for purchasing this report @ https://www.gminsights.com/inquiry-before-buying/810 Gene editing market research report includes in-depth coverage of the industry  with estimates & forecast in terms of revenue in USD billion from 2013 to 2024 , for the following segments: The above information is provided on a regional and country basis for the following: Global Market Insights, Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider; offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy and biotechnology.


News Article | November 18, 2016
Site: marketersmedia.com

Wiseguyreports.Com Adds “Chromatography Systems -Market Demand, Growth, Opportunities and analysis of Top Key Player Forecast to 2021” To Its Research Database This report studies sales (consumption) of Chromatography Systems in Global market, especially in United States, China, Europe, Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering Market Segment by Regions, this report splits Global into several key Regions, with sales (consumption), revenue, market share and growth rate of Chromatography Systems in these regions, from 2011 to 2021 (forecast), like United States China Europe Japan Split by product Types, with sales, revenue, price and gross margin, market share and growth rate of each type, can be divided into Type I Type II Type III Split by applications, this report focuses on sales, market share and growth rate of Chromatography Systems in each application, can be divided into Application 1 Application 2 Application 3 Global Chromatography Systems Sales Market Report 2016 1 Chromatography Systems Overview 1.1 Product Overview and Scope of Chromatography Systems 1.2 Classification of Chromatography Systems 1.2.1 Type I 1.2.2 Type II 1.2.3 Type III 1.3 Application of Chromatography Systems 1.3.1 Application 1 1.3.2 Application 2 1.3.3 Application 3 1.4 Chromatography Systems Market by Regions 1.4.1 United States Status and Prospect (2011-2021) 1.4.2 China Status and Prospect (2011-2021) 1.4.3 Europe Status and Prospect (2011-2021) 1.4.4 Japan Status and Prospect (2011-2021) 1.5 Global Market Size (Value and Volume) of Chromatography Systems (2011-2021) 1.5.1 Global Chromatography Systems Sales and Growth Rate (2011-2021) 1.5.2 Global Chromatography Systems Revenue and Growth Rate (2011-2021) 7 Global Chromatography Systems Manufacturers Analysis 7.1 GE 7.1.1 Company Basic Information, Manufacturing Base and Competitors 7.1.2 Chromatography Systems Product Type, Application and Specification 7.1.2.1 Type I 7.1.2.2 Type II 7.1.3 GE Chromatography Systems Sales, Revenue, Price and Gross Margin (2011-2016) 7.1.4 Main Business/Business Overview 7.2 Bio Rad 7.2.1 Company Basic Information, Manufacturing Base and Competitors 7.2.2 115 Product Type, Application and Specification 7.2.2.1 Type I 7.2.2.2 Type II 7.2.3 Bio Rad Chromatography Systems Sales, Revenue, Price and Gross Margin (2011-2016) 7.2.4 Main Business/Business Overview 7.3 PerkinElmer 7.3.1 Company Basic Information, Manufacturing Base and Competitors 7.3.2 134 Product Type, Application and Specification 7.3.2.1 Type I 7.3.2.2 Type II 7.3.3 PerkinElmer Chromatography Systems Sales, Revenue, Price and Gross Margin (2011-2016) 7.3.4 Main Business/Business Overview 7.4 Pall Corporation 7.4.1 Company Basic Information, Manufacturing Base and Competitors 7.4.2 Nov Product Type, Application and Specification 7.4.2.1 Type I 7.4.2.2 Type II 7.4.3 Pall Corporation Chromatography Systems Sales, Revenue, Price and Gross Margin (2011-2016) 7.4.4 Main Business/Business Overview 7.5 Thermo Scientific 7.5.1 Company Basic Information, Manufacturing Base and Competitors 7.5.2 Product Type, Application and Specification 7.5.2.1 Type I 7.5.2.2 Type II 7.5.3 Thermo Scientific Chromatography Systems Sales, Revenue, Price and Gross Margin (2011-2016) 7.5.4 Main Business/Business Overview 7.6 Gilson 7.6.1 Company Basic Information, Manufacturing Base and Competitors 7.6.2 Million USD Product Type, Application and Specification 7.6.2.1 Type I 7.6.2.2 Type II 7.6.3 Gilson Chromatography Systems Sales, Revenue, Price and Gross Margin (2011-2016) 7.6.4 Main Business/Business Overview 7.7 Agilent 7.7.1 Company Basic Information, Manufacturing Base and Competitors 7.7.2 Machinery & Equipment Product Type, Application and Specification 7.7.2.1 Type I 7.7.2.2 Type II 7.7.3 Agilent Chromatography Systems Sales, Revenue, Price and Gross Margin (2011-2016) 7.7.4 Main Business/Business Overview 7.8 BUCHI 7.8.1 Company Basic Information, Manufacturing Base and Competitors 7.8.2 Product Type, Application and Specification 7.8.2.1 Type I 7.8.2.2 Type II 7.8.3 BUCHI Chromatography Systems Sales, Revenue, Price and Gross Margin (2011-2016) 7.8.4 Main Business/Business Overview 7.9 EMD Millipore 7.9.1 Company Basic Information, Manufacturing Base and Competitors 7.9.2 Product Type, Application and Specification 7.9.2.1 Type I 7.9.2.2 Type II 7.9.3 EMD Millipore Chromatography Systems Sales, Revenue, Price and Gross Margin (2011-2016) 7.9.4 Main Business/Business Overview 7.10 Grace 7.10.1 Company Basic Information, Manufacturing Base and Competitors 7.10.2 Product Type, Application and Specification 7.10.2.1 Type I 7.10.2.2 Type II 7.10.3 Grace Chromatography Systems Sales, Revenue, Price and Gross Margin (2011-2016) 7.10.4 Main Business/Business Overview 7.11 AK Bio 7.12 Shimadzu 7.13 Knauer For more information, please visit https://www.wiseguyreports.com/sample-request/744505-global-chromatography-systems-sales-market-report-2016


News Article | November 16, 2016
Site: www.newsmaker.com.au

Wiseguyreports.Com Adds “Chromatography Systems -Market Demand, Growth, Opportunities and analysis of Top Key Player Forecast to 2021” To Its Research Database This report studies sales (consumption) of Chromatography Systems in Global market, especially in United States, China, Europe, Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering Market Segment by Regions, this report splits Global into several key Regions, with sales (consumption), revenue, market share and growth rate of Chromatography Systems in these regions, from 2011 to 2021 (forecast), like United States China Europe Japan Split by product Types, with sales, revenue, price and gross margin, market share and growth rate of each type, can be divided into Type I Type II Type III Split by applications, this report focuses on sales, market share and growth rate of Chromatography Systems in each application, can be divided into Application 1 Application 2 Application 3 Global Chromatography Systems Sales Market Report 2016 1 Chromatography Systems Overview 1.1 Product Overview and Scope of Chromatography Systems 1.2 Classification of Chromatography Systems 1.2.1 Type I 1.2.2 Type II 1.2.3 Type III 1.3 Application of Chromatography Systems 1.3.1 Application 1 1.3.2 Application 2 1.3.3 Application 3 1.4 Chromatography Systems Market by Regions 1.4.1 United States Status and Prospect (2011-2021) 1.4.2 China Status and Prospect (2011-2021) 1.4.3 Europe Status and Prospect (2011-2021) 1.4.4 Japan Status and Prospect (2011-2021) 1.5 Global Market Size (Value and Volume) of Chromatography Systems (2011-2021) 1.5.1 Global Chromatography Systems Sales and Growth Rate (2011-2021) 1.5.2 Global Chromatography Systems Revenue and Growth Rate (2011-2021) 7 Global Chromatography Systems Manufacturers Analysis 7.1 GE 7.1.1 Company Basic Information, Manufacturing Base and Competitors 7.1.2 Chromatography Systems Product Type, Application and Specification 7.1.2.1 Type I 7.1.2.2 Type II 7.1.3 GE Chromatography Systems Sales, Revenue, Price and Gross Margin (2011-2016) 7.1.4 Main Business/Business Overview 7.2 Bio Rad 7.2.1 Company Basic Information, Manufacturing Base and Competitors 7.2.2 115 Product Type, Application and Specification 7.2.2.1 Type I 7.2.2.2 Type II 7.2.3 Bio Rad Chromatography Systems Sales, Revenue, Price and Gross Margin (2011-2016) 7.2.4 Main Business/Business Overview 7.3 PerkinElmer 7.3.1 Company Basic Information, Manufacturing Base and Competitors 7.3.2 134 Product Type, Application and Specification 7.3.2.1 Type I 7.3.2.2 Type II 7.3.3 PerkinElmer Chromatography Systems Sales, Revenue, Price and Gross Margin (2011-2016) 7.3.4 Main Business/Business Overview 7.4 Pall Corporation 7.4.1 Company Basic Information, Manufacturing Base and Competitors 7.4.2 Nov Product Type, Application and Specification 7.4.2.1 Type I 7.4.2.2 Type II 7.4.3 Pall Corporation Chromatography Systems Sales, Revenue, Price and Gross Margin (2011-2016) 7.4.4 Main Business/Business Overview 7.5 Thermo Scientific 7.5.1 Company Basic Information, Manufacturing Base and Competitors 7.5.2 Product Type, Application and Specification 7.5.2.1 Type I 7.5.2.2 Type II 7.5.3 Thermo Scientific Chromatography Systems Sales, Revenue, Price and Gross Margin (2011-2016) 7.5.4 Main Business/Business Overview 7.6 Gilson 7.6.1 Company Basic Information, Manufacturing Base and Competitors 7.6.2 Million USD Product Type, Application and Specification 7.6.2.1 Type I 7.6.2.2 Type II 7.6.3 Gilson Chromatography Systems Sales, Revenue, Price and Gross Margin (2011-2016) 7.6.4 Main Business/Business Overview 7.7 Agilent 7.7.1 Company Basic Information, Manufacturing Base and Competitors 7.7.2 Machinery & Equipment Product Type, Application and Specification 7.7.2.1 Type I 7.7.2.2 Type II 7.7.3 Agilent Chromatography Systems Sales, Revenue, Price and Gross Margin (2011-2016) 7.7.4 Main Business/Business Overview 7.8 BUCHI 7.8.1 Company Basic Information, Manufacturing Base and Competitors 7.8.2 Product Type, Application and Specification 7.8.2.1 Type I 7.8.2.2 Type II 7.8.3 BUCHI Chromatography Systems Sales, Revenue, Price and Gross Margin (2011-2016) 7.8.4 Main Business/Business Overview 7.9 EMD Millipore 7.9.1 Company Basic Information, Manufacturing Base and Competitors 7.9.2 Product Type, Application and Specification 7.9.2.1 Type I 7.9.2.2 Type II 7.9.3 EMD Millipore Chromatography Systems Sales, Revenue, Price and Gross Margin (2011-2016) 7.9.4 Main Business/Business Overview 7.10 Grace 7.10.1 Company Basic Information, Manufacturing Base and Competitors 7.10.2 Product Type, Application and Specification 7.10.2.1 Type I 7.10.2.2 Type II 7.10.3 Grace Chromatography Systems Sales, Revenue, Price and Gross Margin (2011-2016) 7.10.4 Main Business/Business Overview 7.11 AK Bio 7.12 Shimadzu 7.13 Knauer

Loading Bio Rad collaborators
Loading Bio Rad collaborators